Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arecor Therapeutics's EBITDA for the
six
months ended in Dec. 2025 was €4.16 Mil. Arecor Therapeutics's Revenue for the
six
months ended in Dec. 2025 was €-0.33 Mil. Therefore, Arecor Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was -1,261.52%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Arecor Therapeutics EBITDA Margin % Related Terms
Arecor Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6UI vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Arecor Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (STU:6UI) has a EBITDA Margin % of -1,261.52% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arecor Therapeutics and its competitors. According to the industry distribution chart, Arecor Therapeutics ranks #30 out of 941 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Arecor Therapeutics' EBITDA Margin % too high?
Arecor Therapeutics' current EBITDA Margin % is -1,261.52%. Based on the distribution chart, Arecor Therapeutics ranks #30 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #30 out of 941 companies for EBITDA Margin %. This places Arecor Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current EBITDA Margin % is -1,261.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current EBITDA Margin % of -1,261.52%. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current EBITDA Margin % is -1,261.52%. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current EBITDA Margin % is -1,261.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.
Key valuation signals for STU:6UI:
EBITDA Margin %: -1,261.52%
GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for STU:6UI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6UI has been successfully added to your 
